HOPA Member Award Winners

2024 - Not Awarded

2023 - Casey B. Williams, PharmD, MBA, BCOP, FHOPA

2020-22 - Not Awarded

2019 - George Carro, RPh, MS, BCOP

2018 - R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

2017 - Terri G. Davidson, PharmD, BCCP, BCOP, FASHP

2016 - Niesha L. Griffith, MS, RPh, FASHP

2015 - David W. Henry, MS, BCOP, FASHP

2014 - Rowena N. Schwartz, PharmD, BCOP

2013 - Robert Ignoffo, PharmD, FASHP, FCSHP

2012 - Susan Goodin, PharmD

2011 - Jim Koeller, MS

2010 - Val R. Adams, PharmD, FCCP, BCOP

2009 - Barry R. Goldspiel, PharmD, BCOP, BCPS, FASHP, FISOPP

2008 - Carol M. Balmer, PharmD, BCOP

2007 - Jane M. Pruemer, PharmD, BCOP, FASHP

2006 - Judy L. Chase, PharmD, FASHP

2006 - Amy W. Valley, PharmD, BCOP

2005 - LeAnne D. Kennedy, BCOP

2024 - Onyebuchi Ononogbu, PharmD, BCOP

2023 - Zanette Kanani Bradley, PharmD, BCOP

2023 - Mya Merrow, PharmD, BCOP

2022 - Maurice Alexander, PharmD, BCOP

2022 - Britny R. Brown, PharmD, BCOP

2024 - Benjamin Andrick, PharmD, BCOP

2023 - Sarah Cimino, PharmD, BCOP

2023 - C. Brooke Adams, PharmD, BCOP

2022 - Kathryn Maples, PharmD, BCOP

2021 - Justin Arnall, PharmD, BCOP

2020 - Kirollos S. Hanna, PharmD, BCPS, BCOP

2020 - Megan N. Dillaman, PharmD, BCOP

2019 - Megan May, PharmD, BCOP

2018 - Alexandra Shillingburg, PharmD, BCOP

2017 - Amber Bradley Clemmons, PharmD, BCOP

2016 - Kristin Held Wheatley, PharmD, BCOP

2015 - Patrick J. Kiel, PharmD, BCPS, BCOP

2014 - Robert S. Mancini, PharmD, BCOP

2013 - Steve Stricker, PharmD, MS, BCOP

2012 - Daniel Zlott, PharmD, BCOP

2011 - Trevor McKibbin, PharmD, MS, BCPS

2010 - LeAnn Best Norris, PharmD, BCPS, BCOP

2009 - Julianna Burzynski, PharmD, BCPS, BCOP

2008 - Janet Espirito, PharmD, BCOP

2024 - Stephen J. Lirette, PharmD, BCOP

2023 - Allison Kane, PharmD

2022 - Sarah E. Wheeler, PharmD, BCOP

2021 - Megan Langer, PharmD, BCOP

2020 - Kathy Hogan Edwards, PharmD, BCPS, BCOP

2019 - Ashley Glode, PharmD, BCOP

2018 - Not Awarded

2017 - Kerry Parsons, PharmD, BCOP, FHOPA

2016 - Benyam Muluneh, PharmD, BCOP, CPP

2015 - Rowena N. Schwartz, PharmD, BCOP

2014 - Sarah S. Hudson-DiSalle, PharmD, RPh

2024 - Heather Cranford, CPhT

2023 - Tabitha Sowers Alvarado, AA, CPhT

2022 - Alicia M. Holguin, CPhT

2022- May Lo, PharmD, RPh

2021 - Emily Zimdars, BA, CPhT

2021 - Jessica Turner, CPhT

2020 - Alexamil Rodriguez, CPhT

2019 - Amanda Pate, CPhT

2018- Desiree Rolniak, CPhT

2017 - Cheryl Hyk, MA, CPhT

2016 - Edward D. Gormley, BS, CPhT

2012-2015 - Not Awarded

2011 - Tanja Monroe

2010 - Therese McGrain, CPhT

2009 - Jeanne Anderson, CPhT

2008 - Kenneth Grohgans, CPhT

2007 - Darrell Clarke, CPhT

2007 - Anne Hameed, CPhT

2024 - Shawn Patrick Griffin, PharmD, BCOP

2023 - C. Brooke Adams, PharmD, BCOP

2022 - Mallika P. Patel, PharmD, CPP

2020 - Eve-Michell Segal, PharmD, BCOP

2021 - Not Awarded

2019 - Ila Saunders, PharmD, BCOP

2024 - Julie Kennerly-Shah, PharmD, MS, MHA, BCP

2023 - Robert S. Mancini, PharmD, BCOP, FHOPA

2022 - Not Awarded

2021 - Ali McBride, PharmD, MS

2024 - Lisa Holle, PharmD, BCOP, FHOPA, FISOPP

2024 - Rebecca Fahrenbruch, PharmD, BCOP, FHOPA

2024 - Melissa Carroll, PharmD, BCPS, Koselke E, Howell J, et al. The clinical and financial impact of remote clinical oncology pharmacist engagement in community-based practices within The US Oncology Network. Journal of Oncology Pharmacy Practice. 2023; 0(0). DOI: 10.1177/10781552231173860

2023 - Jonathan Cohen, PharmD, BCOP, Lee C, Markham R, Szerwo J, Roska M, Bubalo J. Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists. J Am Coll Clin Pharm. 2022;1-53. DOI: 10.1002/jac5.1698

2022 - Shannon Hough, PharmD, BCOP, Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage JB. Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncol Pract. 2021 Feb 3:OP2000639. doi: 10.1200/OP.20.00639

2021 - Grant Lee, PharmD, Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NTN. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Sep 17;1078155220957738. PubMed PMID: 32938297.

2020 - Jacqueline L. Olin, M.S., PharmD, BCPS, Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother 2019 Aug;53(8):812-832. doi: 10.1177/1060028019833038. Epub 2019 Feb 15.

2019 - Julianne Orr, PharmD BCOP, Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, Deremer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018;24(10):2065–71.

2018 - NA

2017 - Karen Sweiss, PharmD, Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016; e-pub ahead of print 16 May 2016; doi:10.1038/bmt.2016.136.

2016 - Ginah Nightingale, PharmD BCOP, Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453-1459.

2015 - Joseph S. Bubalo, PharmD BCOP BCPS, Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi:10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23.

2014 - Ali McBride, PharmD MS BCPS BCOP, McBride A, Lathon S, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. Pharmacotherapy. 2013;33(3):295-303.

2013 - Kamakshi V. Rao, PharmD BCOP CPP, Strother RM, Rao KV, Gregory KM, Jakait B, Busakhala N, Schellhase E, Pastakia S, Krzyzanowski M, Loehrer PJ. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012. Jan 16

2012 - Kristine R. Crews, PharmD, BCPS, Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011

2011 - NA

2010 - Brian Crandell, PharmD, BCOP, O'Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632-9.

2024 - Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh, Ng DQ, Ritt-Olson A, Freyer DR, Miller KA, Thomas SM, Milam J. Substance Use Among Young Adult Survivors of Childhood Cancer With Cognitive Impairment: An Analysis of the Project 4 Forward Cohort. JCO Oncol Pract. 2023 Mar;19(3):e345-e354. DOI: 10.1200/OP.22.00458. Epub 2022 Dec 12. PMID: 36508698; PMCID: PMC10022886.

2023 - Aaron W. Stewart, PharmD, CTTS, Shillingburg A, Petros W, Wen S, Piktel D, Moses R, Gibson LF, Craig M, Cumpston A. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls. Pharmacotherapy. 2022 Jan;42(1):53-57. doi: 10.1002/phar.2646. Epub 2021 Nov 22. PMID: 34767652.

2022 - Lydia Benitez, PharmD, BCOP Benitez, LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378. Epub ahead of print. PMID: 33830856.

2021 - Victoria Nachar, PharmD, BCOP, Hoylman E, Brown A, Perissinotti A, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020 Mar;61(3):691-698

2020 - Daniel J. Crona, PharmD, PhD, CPP, Crona DJ, Skol AD, Leppänen V-M, Glubb DM, Etheridge AS, Hilliard E, Peña C, Peterson Y, Klauber-DeMore N, Alitalo KK, Innocenti F. Novel genetic determinants of survival in renal cell carcinoma patients treated with sorafenib: a clinical and translational experimental study. Cancer Res. 2019 Jan; 79(1):231-241. PMCID: PMC6541205.

2019 - Judith A. Smith, BS PharmD BCOP CPHQ FCCP FISOPP, Cotton S, Brown RE, Nugent EK, Robazetti SC, Berens PD, Smith JA. Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. Obstetrics & Gynecology. 2018Apr;131(4):681–7.

2018 - NA

2017 - NA

2016 - Meghana V. Trivedi, PharmD PhD BCOP, Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct;153(3):591-7. Epub 2015 Sep 4.

2015 - David J. Reeves, PharmD BCOP, Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014 Sep;78(3):565-71. Doi: 10.1111/bcp.12384 PMID: 24646036

2014 -Casey B. Williams, PharmD BCOP, Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. Pharmacotherapy. 2013 Jun 24. doi: 10.1002/phar.1316.

2013 - Wendelin Nelson, PharmD BCOP, Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract 2012;18(3):323-332.

2012 - Cindy O'Bryant, PharmD BCOP FCCP, O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2011 Sep 22

2011 - Jacob K. Kettle, PharmD, Kettle JK, Grauer D, Folker TL, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy. 2010;30(8):812-817.

2010 - LeAnne Kennedy, PharmD, BCOP, Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48:2285-91.

2009 - Stacy S. Shord, PharmD, BCOP, Sandra Cuellar, PharmD, BCOP, Shord SS, Hamilton JM Jr, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract. 2008;14:5-22.

2007 - Donald A. Hutcherson, RPh Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26:242-247.

2006 - Susan Goodin, PharmD, BCOP, Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117-142

2007 - Dominic A. Solimando Jr, MA, RPh, BCOP, FAPhA, FASHP

2006 - David Baribeault, RPh, BCOP and Sachin Shah, PharmD, BCOP

2024 - Kayleigh R. Marx, PharmD, BCOP